Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Colorectal Neoplasms 29Prostatic Neoplasms 28Neoplasms 28Breast Neoplasms 27Neoplasm Metastasis 26Multiple Myeloma 24Pancreatic Neoplasms 22Recurrence 18Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Melanoma 17Lymphoma, Non-Hodgkin 17Triple Negative Breast Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 14Lung Neoplasms 13Carcinoma, Renal Cell 13Stomach Neoplasms 12Lymphoma, Follicular 12Lymphoma 12Endometrial Neoplasms 12Advanced Solid Tumors 12Small Cell Lung Carcinoma 11Glioblastoma 11Colonic Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 10Uterine Cervical Neoplasms 9

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Intestinal Neoplasms × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05379985 2026-05-15

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Revolution Medicines, Inc.

Phase 1/2 Recruiting
754 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplastic Processes, Pancreatic Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡